Trial Profile
Pilot Study for Evaluating the Efficacy and Tolerability of Induction Therapy With Recombinant Human Erythropoietin Beta (rHuEPO) NeoRecormon® - at High Dose in Anemic Cancer Patients Treated With Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Epoetin beta (Primary) ; Epoetin beta (Primary)
- Indications Anaemia; Cancer
- Focus Therapeutic Use
- Sponsors Roche
- 13 May 2016 New trial record